Search research articles
Contact Us
Filters
Showing results (131-140 of 153) with videos related to
Page
of 16
Sort By:
JAMA
|
July 25, 2014
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial
Andrew X Zhu, Masatoshi Kudo, Eric Assenat, et al.
British Journal of Cancer
|
February 3, 2021
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
Andrew X Zhu, Richard S Finn, Yoon-Koo Kang, et al.
JHEP Reports : Innovation in Hepatology
|
January 4, 2021
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
Masatoshi Kudo, Peter R Galle, Giovanni Brandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2017
Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer
Alexandre Prieur, Monica Cappellini, Guillaume Habif, et al.
BMC Cancer
|
July 29, 2023
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)
Angélique Vienot, Marion Jacquin, Magali Rebucci-Peixoto, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 12, 2025
Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: An AGEO study
Iona Campo-Le-Brun, Emma Grapinet, Valerie Aurillac, et al.
Journal for Immunotherapy of Cancer
|
May 31, 2023
Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series
Cyrille Coustal, Juliette Vanoverschelde, Xavier Quantin, et al.
The Lancet. Oncology
|
May 24, 2014
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
David Malka, Pascale Cervera, Stéphanie Foulon, et al.
The Lancet. Oncology
|
January 23, 2019
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2013
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study
Josep M Llovet, Thomas Decaens, Jean-Luc Raoul, et al.
Page
of 16
Search research articles
Search
Showing results (131-140 of 153) with videos related to
Sort By:
Page
of 16
JAMA
|
July 25, 2014
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial
Andrew X Zhu, Masatoshi Kudo, Eric Assenat, et al.
British Journal of Cancer
|
February 3, 2021
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
Andrew X Zhu, Richard S Finn, Yoon-Koo Kang, et al.
JHEP Reports : Innovation in Hepatology
|
January 4, 2021
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
Masatoshi Kudo, Peter R Galle, Giovanni Brandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2017
Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer
Alexandre Prieur, Monica Cappellini, Guillaume Habif, et al.
BMC Cancer
|
July 29, 2023
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)
Angélique Vienot, Marion Jacquin, Magali Rebucci-Peixoto, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 12, 2025
Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: An AGEO study
Iona Campo-Le-Brun, Emma Grapinet, Valerie Aurillac, et al.
Journal for Immunotherapy of Cancer
|
May 31, 2023
Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series
Cyrille Coustal, Juliette Vanoverschelde, Xavier Quantin, et al.
The Lancet. Oncology
|
May 24, 2014
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
David Malka, Pascale Cervera, Stéphanie Foulon, et al.
The Lancet. Oncology
|
January 23, 2019
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2013
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study
Josep M Llovet, Thomas Decaens, Jean-Luc Raoul, et al.
Page
of 16